Recent Technology Transfer Initiatives

More recently, the LMB’s technology transfer initiatives include:

• Founding of Heptares Therapeutics (2007) to exploit pioneering new technology to stabilise G-protein-coupled receptors.
• Creation of Bicycle Therapeutics (2009) to develop a novel technology platform for the creation of a new generation of biotherapeutics.
• Setting up of Mesolens Ltd (2009) to develop the technology behind Mesolens microscopy, a new type of imaging that can reach deeper into solid tissues such as embryos or tumours.
• Licensing of an anti-IL-25 antibody, as a potential asthma treatment.
• Commercial licensing of gold EM support grids to Quantifoil.

MRC Technology is also considering options for the commercialisation of Jason Chin’s work on protein therapeutics; and research by David Komander on ubiquitin biology.